Company Filing History:
Years Active: 2020-2023
Title: Cristian Rodriguez: Innovator in Monoclonal Antibodies
Introduction
Cristian Rodriguez is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for treating inflammatory and autoimmune diseases.
Latest Patents
Rodriguez's latest patents include groundbreaking inventions related to IP-10 antibodies and their uses. The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity. These antibodies inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux, and inhibit IP-10-induced cell migration. Additionally, the invention encompasses nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods for expressing these antibodies. Furthermore, it includes immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies. The invention also outlines methods for inhibiting IP-10 activity using these antibodies, which can be instrumental in treating various inflammatory and autoimmune diseases.
Career Highlights
Cristian Rodriguez is currently employed at Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His work at this leading biopharmaceutical company allows him to collaborate with other experts in the field and contribute to innovative healthcare solutions.
Collaborations
Rodriguez has worked alongside talented colleagues such as Mohan Srinivasan and Shrikant Deshpande. Their collaborative efforts have further enhanced the research and development of novel therapeutic approaches.
Conclusion
Cristian Rodriguez is a prominent inventor whose work in monoclonal antibodies has the potential to transform treatments for inflammatory and autoimmune diseases. His contributions to the field are invaluable, and his ongoing research promises to yield significant advancements in biotechnology.